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Abstract
Backgrounds: The failure of current Standard Short-Course Chemotherapy (SCC) in new and previously treated
cases with tuberculosis (TB) was mainly due to drug resistance development. But little is known on the
characteristics of acquired drug resistant TB during SCC and its correlation with SCC failure. The objective of the
study is to explore the traits of acquired drug resistant TB emergence and evaluate their impacts on treatment
outcomes.
Methods: A prospective observational study was performed on newly admitted smear positive pulmonary TB (PTB)
cases without drug resistance pretreatment treated with SCC under China’s National TB Control Program (NTP)
condition from 2008 to 2010. Enrolled cases were followed up through sputum smear, culture and drug
susceptibility testing (DST) at the end of 1, 2, and 5 months after treatment initiation. The effect factors of early or
late emergence of acquired drug resistant TB , such as acquired drug resistance patterns, the number of acquired
resistant drugs and previous treatment history were investigated by multivariate logistic regression; and the impact
of acquired drug resistant TB emergence on treatment failure were further evaluated.
Results: Among 1671 enrolled new and previously treated cases with SCC, 62 (3.7 %) acquired different patterns of
drug resistant TB at early period within 2 months or later around 3–5 months of treatment. Previously treated cases
were more likely to develop acquired multi-drug resistant TB (MDR-TB) (OR, 3.8; 95 %CI, 1.4–10.4; P = 0.015).
Additionally, acquired MDR-TB cases were more likely to emerge at later period around 3-5 months after treatment
starting than that of non-MDR-TB mainly appeared within 2 months (OR, 8.3; 95 %CI, 1.7–39.9; P = 0.008). Treatment
failure was associated with late acquired drug resistant TB emergence (OR, 25.7; 95 %CI, 4.3–153.4; P < 0.001) with
the reference of early acquired drug resistant TB emergence.
Conclusions: This study demonstrates that later development of acquired drug resistant TB during SCC is liable to
suffer treatment failure and acquired MDR-TB pattern may be one of the possible causes.
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Background
TB is a major global health problem with 8.6 million
new cases and almost 1.3 million deaths attributed to
the disease every year [1]. WHO recommended stan-
dardized first-line anti-TB drug regimen is a single 6-
month or 8-month regimen composed of isoniazid (H),
rifampicin (R), ethambutol (E), and streptomycin (S)
with pyrazinamide (Z) [2]. This regimen is recom-
mended for all new TB cases and previously treated
cases in more than 90 countries. This strategy is
designed and evaluated as the cost-effectiveness regimen
used in resource-limited settings for decades for the
consideration of convenient treatment management
based on same number, dose, and types of medication.
Though high cure rate was achieved of SCC for cases
with drug-sensitive TB [3], the emergence of drug resist-
ant TB, especially MDR-TB, and acquisition of add-
itional drug resistance during treatment, brought much
less efficacy of SCC both in trials [4–7] and under pro-
gram conditions [8]. Few cohort studies, though the
sample size was small, worked on the treatment of
mono- or poly-resistant TB with SCC and presented
poor results [9]. In most low- and middle-income coun-
tries, DST is not routinely performed for new cases nor
for most previously treated cases [10, 11]; therefore,
cases carrying drug-resistant strains of Mycobacterium
tuberculosis (MTB) might be at greater risk for SCC fail-
ure and disseminating drug resistant strains [12]. China
is one of the 27 countries with high MDR-TB burden,
early detection and treatment could help prevent its
transmission. Currently, China’s NTP [13] provides new
and previously treated cases with SCC under directly ob-
served treatment (DOT) and monitors their response to
SCC by sputum smear (SS) rather than sputum culture
and DST due to limited resources. Sputum culture and
DST are recommended to be performed for cases with
initial treatment and retreatment failure, where possible,
to develop appropriate chemotherapy regimens. Hence,
little is known whether drug resistant TB occurs during
treatment and few data available links acquired drug
resistant TB to treatment failure with SCC. To address
these issues, we conducted a prospective observational
study tracing the emergence of acquired drug resistant
TB at indicated time points among new and previously
treated cases receiving first-line standard regimens to
determine the characteristics and its effect on treatment
failure.
Methods
Study settings and population
A prospective and observational cohort study was con-
ducted in 8 provinces including Tianjin, Hebei, Henan,
Shanghai, Chongqing, Yunnan, Guangxi, and Guangdong
which are situated in northern, eastern, central-western,
and southern China from October 2008 to September
2010. This study was embedded in the routine TB con-
trol program of each province. Case detection, smear
microscopy, chemotherapy and treatment management
were routine procedures under NTP; sputum culture
and DST at varied time points were added. The sample
size for new and previously treated cases of sputum
smear-positive (SS+) TB was set at 1927 and 506 re-
spectively which took into account a prevalence of
overall resistance to first-line anti-TB drugs (H, R, E, S)
of 18.6 % and 46.5 % respectively from a previous study
[14], with desired precision of 1 %, a 95 % confidence
level and a non-response rate of 10 %, assuming that
15 % of the culture samples would be lost due to failure
to recover or due to growth of non-tuberculosis myco-
bacterium (NTM). Based on the requirements for sam-
ple size and the capacity to perform sputum culture
and DST, the provincial TB Control and Prevention
Centers in the above provinces were selected. The
number of cases allocated to each province was based
on the number of new SS+ cases reported by that prov-
ince with the proportion to the total number of cases
nationwide in 2007. Study subjects meeting all the fol-
lowing criteria were enrolled: 1. Aged ≥14 years; 2.
Informed consent; 3. Newly registered confirmed PTB
cases including cases with two positive direct smear mi-
croscopy results; or one positive direct smear micros-
copy result and lung imaging consistent with active PTB
imaging manifestations [13]. 4. Not NTM strains infec-
tion; 5. Strains susceptible to all 4 first line anti-TB drugs
(H, R, E, S) pretreatment (month 0). Demographic infor-
mation and relevant medical history including age, gender,
physical examinations, previous anti-TB treatment history
and contact history with TB index cases were collected
with a standard questionnaire given upon study entry. SS,
culture, and DST results were examined at month 1, 2,
and 5. Treatment outcomes were evaluated for both pan-
susceptible cases all through SCC and acquired drug
resistant TB cases during SCC.
Definitions
New cases of TB were defined as those who had never
been treated for TB or had taken anti-TB drugs for less
than one month. Previously treated cases were defined
as those who had been previously treated for one month
or more with anti-TB drugs [13]. In our study, according
to the time of acquired drug resistant TB emergence for
the first time, cases with any drug resistant TB emer-
gence before the end of 2 months after treatment initi-
ation were defined as early emergence of drug resistance
while cases with drug resistant TB emergence after
2 months were defined as late emergence of drug resist-
ance. Treatment outcomes were defined according to
the WHO guidelines [2]. A patient who was initially SS+
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and who was sputum smear-negative in the last month
of treatment and on at least one previous occasion was
defined as “Cured”. A patient who completed treatment
but did not meet the criteria for cure or failure was
defined as “Completed treatment”. A patient who died
from any cause during treatment was defined as “Died”.
A patient who was initially SS+ and who remained SS+
at month 5 or later during treatment was defined as
“Failed”. A patient whose treatment was interrupted for
two consecutive months or more was defined as
“Defaulted”. A patient whose treatment outcome was
not known was defined as “Not evaluated”. For analysis,
a patient who was cured or who completed treatment
was combined as “Successfully treated”. In this study we
mainly focus on cases with treatment success and failure
of SCC.
Treatment regimen
All cases with pan-susceptible MTB strains prior treat-
ment received SCC under qualified DOT. The initial
standard regimen was 2H3R3Z3E3/4H3R3, and the retreat-
ment standard regimen was 2H3R3Z3E3S3/6H3R3E3 [13].
For patients who could not use streptomycin for any rea-
son, the intensive phase was extended for an additional
month as 3H3R3Z3E3/6H3R3E3. The following regimen
modifications were made after the second month SS
examination: First, if a new SS+ TB patient was still tested
SS+ at the end of the second month, the intensive phase
was extended for an additional month, and the continu-
ation phase remained unchanged. A smear microscopy
was performed at the end of the third month. If the SS
was negative at the end of the fifth month, the treatment
regimen was 3H3R3Z3E3/4H3R3. Second, if a retreatment
SS + TB patient had a positive SS at the end of the second
month, the intensive phase was extended for an additional
month if the treatment regimen contained streptomycin
and the continuation phase remained unchanged as
3H3R3Z3E3S3/6H3R3E3, or the intensive phase was
extended for another month, if the treatment regimen did
not contain streptomycin, and the continuation phase
remained unchanged as 4H3R3Z3E3/6H3R3E3. In both
cases, a smear microscopy was performed at the end of
the third month.
Bacteriologic examination
Three consecutive sputum samples (spot, night, and
morning) were collected before the initiation of treat-
ment (month 0) and 2 sputum samples were collected at
months 1, 2, and 5 for each eligible patient. For isolation
of the culture, each specimen was decontaminated,
digested, and homogenized using the standard Petroff
method [15]. An aliquot of 0.1 ml of the resulting speci-
men was inoculated into acidified Löwenstein–Jensen
(LJ) slant tubes for primary isolation of the organism.
Tubes were then incubated at 37 °C and inspected for
growth of Mycobacterium for a period of 8 weeks. If no
bacteria grew by week 8, the result was recorded as
negative. Cultures with growing colonies were contin-
ued for identification and DST. Susceptibility testing of
TB isolates to four first-line antimicrobial agents was
performed by the indirect proportion method with LJ
medium. The following drug concentrations were used
to distinguish resistant isolates from susceptible isolates:
isoniazid (H, 0.2 μg/mL), rifampicin (R, 40 μg/mL), eth-
ambutol (E, 2 μg/mL), and streptomycin (S, 4 μg/mL). A
strain was considered resistant when bacterial growth
on a drug-containing medium was equal to or greater
than 1 % of the colonies that grew on a drug-free
medium. Quality-assured DST is critical to ensure accur-
ate detection of drug resistance for subsequent treatment
decisions and to avoid false diagnosis. All laboratories en-
gaging in this study had external quality assessment cover-
age of DST. Internal control of sensitivity testing was
assessed using a MTB sensitive strain (H37Rv).
Ethical considerations
This study was reviewed and approved by the Institu-
tional Ethics Review Committee of Beijing Chest Hos-
pital, Capital Medical University, Beijing Tuberculosis
and Thoracic Tumor Research Institute, and selected
8 provincial TB Control and Prevention Centers.
Written informed consent was obtained from all SS+
cases before enrollment in the study. In particular, for
the minors enrolled in the study, written informed
consent was obtained from themselves and their par-
ents or guardians before enrollment. DST results were
promptly reported back to the respective local health
facilities the patients visited for further treatment
management from above selected areas.
Statistics
The categorical variables were analyzed using Pear-
son’s Chi-square test or Fisher’s exact test as appro-
priate. To evaluate the effect factors of acquired drug
resistant TB emergence, variables significant (p < 0.05)
in the univariate analysis were subsequently analyzed
by multiple logistic regression with a stepwise and
forward method to identify the statistically significant
factors to be maintained in the final model. For ex-
ploring the effect of acquired drug resistant TB emer-
gence on treatment failure, we compared cases with
late emergence to those with early emergence using
univariate analysis by computing odds ratios (ORs)
and their 95 % confidence intervals (CI). Data analysis
was performed using SPSS version 18.0 (SPSS, Chi-
cago). P value <0.05 was considered as criterion for
statistical significance.
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Results
Patient enrollment and demographic characteristics
During the study period, among 2142 confirmed pul-
monary TB cases detected, 67 cases infected with NTM,
29 cases declined to participate the study, 321 cases with
drug resistant TB and 54 cases with negative sputum
culture results before treatment initiation. Therefore, ac-
cording to the inclusion and exclusion criteria, the above
cases were excluded and a total of 1671 pan-susceptible
TB cases to all four first-line anti-TB drugs confirmed
by pretreatment DST were enrolled and then received
standardized anti-TB treatment (Fig. 1). Of these 1671
pan-susceptible cases pretreatment, 62 cases developed
drug resistant TB during anti-TB therapy. Table 1 showed
the analysis of univariate risk factors for acquired MDR-
TB and Non-MDR-TB respectively. Non-MDR-TB refers
to the cases with drug resistance other than MDR-TB. We
found those aged 40–59 years (OR, 17.5; 95 %CI, 2.3–
134.6; P < 0.001) was a significant factor for acquired
MDR-TB development. Cases who had received previous
TB treatment (OR, 3.8; 95 %CI, 1.4–10.4; P = 0.015) were
more likely to develop acquired MDR-TB.
Acquired drug resistant TB emergence and its
characteristics
Before starting treatment, 321 cases were resistant to at
least one of the four first-line anti-TB drugs (H, R, E,
and S), of which 251 were new and 70 were previously
treated; 1671 cases were susceptible to all four drugs
tested, of which 62 acquired drug resistant TB during
SCC, composed of 49 new and 13 previously treated
cases. The overall prevalence of drug resistance in our
study was 17.6 % (300 of 1707) of new cases and 29.1 %
(83 of 285) of previously treated cases. Furthermore, the
prevalence of MDR-TB was 2.6 % (45 of 1707) of new
cases and 14.0 % (40 of 285) of previously treated cases
in the study (Additional file 1: Table S1). For the 62
acquired drug resistant TB cases, 89.8 % of new (44 of
49) and 61.5 % (8 of 13) of previously treated cases de-
veloped drug resistance within 2 months of SCC. In
addition, 75.0 % newly acquired drug resistant TB (39 of
52) cases were resistant to 1 or 2 anti-TB drugs within
first 2 months, while 70.0 % newly acquired drug resist-
ant TB cases were resistant to 3 or 4 anti-TB drugs dur-
ing 3–5 months after treatment starting. The acquired
drug resistance patterns appeared within 2 months were
mainly non-MDR-TB, accounted for 80.8 % (42 of 52)
among patients with acquired drug resistance of same
period, while 3–5 months after treatment starting,
70.0 % (7 of 10) newly acquired drug resistant TB cases
were of MDR-TB pattern. In multivariate logistic regres-
sion analysis, late emergence of acquired drug resistant
TB was associated with drug resistance patterns. Ac-
quired MDR-TB cases were more likely to emerge at
later period than that of acquired non-MDR-TB cases
(OR, 8.3; 95 %CI, 1.7–39.9; P = 0.008) (Table 2).
Treatment outcomes of acquired drug resistant TB cases
with standardized regimen
84.3 % of cases with pan-susceptible TB throughout
were successfully treated and similar treatment success
rate was achieved of cases with acquired drug resistant
TB within 2 months of SCC, while only 20 % cases with
late drug resistant TB emergence after 2 months were
successfully treated (Table 3). The impact of time points
of acquired drug resistant TB emergence on treatment
outcomes evaluated indicated that treatment failure was
significantly more likely among late emergence cases
than among early emergence cases (OR, 25.7; 95 %CI,
4.3–153.4; P < 0.001) (Table 4). In addition, we analyzed
the treatment outcomes of 62 acquired drug resistant
cases during SCC based on drug resistance patterns. The
treatment success rate of acquired MDR-TB cases was
52.9 %, much lower than that with non-MDR-TB pattern
at 82.2 %.We further analyzed treatment success rate of
3 subgroups of non-MDR-TB. It is reported 92.3 % cases
with any H resistance and 89.5 % cases with E/S resist-
ance were successfully treated respectively. However, the
treatment success rate of cases with any R resistance
was 61.5 % (Additional file 1: Table S2).
Discussion
Up to date, this study is the first to evaluate traits of ac-
quired drug resistant TB emergence and its impact on
treatment failure of SCC under China’s routine NTP
condition. Majority of acquired drug resistant TB cases
developed early within 2 months with SCC and late ac-
quired drug resistant TB emergence after 2 months is
more likely associated with the drug resistance pattern
of MDR-TB. Furthermore, our results indicated a good
Fig. 1 Flow chart of TB subjects enrolled in the study
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response to SCC in cases with pan-susceptible strains
throughout therapy which reconfirmed the SCC effective-
ness for cases with susceptible strains [8, 16]. However,
our findings presented poor response of SCC in cases with
acquired drug resistant TB, especially with late drug resist-
ant TB. It is shown that late acquired drug resistant TB
emergence after 2 months is 25.7 times higher to result in
treatment failure than that within 2 months.
In our study, the data from 8 provinces in China indi-
cating a overall drug resistant TB prevalence of 17.6 %
in new cases and 29.1 % in previously treated cases and
a MDR-TB prevalence of 2.6 % and 14.0 % in new and
Table 1 Demographic characteristics and risk factors for patients with acquired drug resistant TB during SCC
Characteristics Pan-susceptible TB throughouta
n = 1609(%)






MDR-TBc n = 17(%) Non-MDR-TBd n = 45(%) OR (95 % CI)e P value OR(95 % CI) P value
Age(years)
<40 756(47.0) 1(5.9) 19(42.2) Reference Reference
40–59 560(34.8) 13(76.5) 20(44.5) 17.5(2.3–134.6) <0.001 1.4(0.8–2.7) 0.278
≥60 293(18.2) 3(17.6) 6(13.3) 7.7(0.8–74.7) 0.07g 0.8(0.3–2.1) 0.665
Gender
Male 1160(72.1) 14(82.4) 35(77.8) Reference Reference
Female 449(27.9) 3(17.6) 10(22.2) 0.6(0.2–1.9) 0.427g 0.7 (0.4–1.5) 0.401
BMIf (Kg/m2)
BMI < 18.5 620(38.5) 3(17.6) 18(40.0) Reference Reference
BMI≥ 18.5 989(61.5) 14(82.4) 27(60.0) 2.9(0.8–10.2) 0.078 0.9(0.5–1.7) 0.842
Treatment history
New 1407(87.4) 11(64.7) 38(84.4) Reference Reference
Previously treated 202(12.6) 6(35.3) 7(15.6) 3.8(1.4–10.4) 0.015g 1.3(0.6–2.9) 0.550
aPan-susceptible TB throughout in our study was defined as cases with TB strains susceptible to all four first-line anti-TB drugs including soniazid(H), rifampicin(R),
ethambutol(E), and streptomycin(S) both pretreatment and throughout therapy
bAny acquired drug resistant TB in our study was defined as cases with TB strains that were susceptible to all four first-line anti-TB drugs pretreatment, but developed
resistance to at least one of the four drugs during SCC
c MDR-TB was defined as TB that was at least resistant to both isoniazid and rifampicin
dNon-MDR-TB in our study was defined as TB cases with any drug resistance pattern except MDR-TB
eOR, odds ratio. CI, confidence interval
fBMI, body mass index, calculated as the weight in kilograms divided by the square of the height in meters
gP value was determined by Fisher’s Exact Test. Not indicated was determined by Pearson’s Chi-Square Test
Table 2 Frequency and effect factors of acquired drug resistant TB emergence at varied time points during SCC
Variable Month1(1)
n = 35 (%)
Month2(2)
n = 17 (%)
Month3-5(3)
n = 10 (%)
Univariate analysis
(3) vs (1 + 2)
Multivariate logistic regression (3) vs (1 + 2)
P value OR(95 % CI) P value
Treatment history 0.027*
New 32 (91.4) 12 (70.6) 5 (50.0)
Previously treated 3 (8.6) 5 (29.4) 5 (50.0)
No. of drugs to which isolate is resistant 0.015*
1 21(60) 6(35.3) 2(20.0)
2 9(25.7) 3(17.6) 1(10.0)
3 4(11.4) 5(29.5) 5(50.0)
4 1(2.9) 3(17.6) 2(20.0)
Drug resistance patterns 0.003*
Non-MDR-TB 30 (85.7) 12 (70.6) 3 (30.0) Reference
MDR-TB 5 (14.3) 5 (29.4) 7 (70.0) 8.3(1.7–39.9) 0.008
*P value was determined by Fisher’s Exact Test
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previously treated cases respectively are lower than that
from China’s national drug resistance survey in 2007
[17]. The reduction of drug resistant TB and MDR-TB
prevalence in our study could be explained by two pos-
sible reasons. Firstly, given the prevalence of TB and
MDR-TB not balanced which was highest in western
China, 2 provinces from 4 main areas in the study may
not be representative of the overall situation in China.
Secondly, the drug resistant TB cases in the study were
from TB Control and Prevention Centers system not TB
specialized hospitals system where more previously
treated cases tend to access for further second line anti-
TB drugs due to MDR-TB pretreatment [18].
It is well known that previous TB treatment is a strong
determinant of drug resistance [17, 19–22]. Current data
suggests that previously treated cases are more likely to
develop acquired drug resistance, especially MDR-TB,
during therapy than that of new cases. However, it is im-
possible for us to determine the identified reason of ac-
quired drug resistant TB during SCC without DNA
fingerprinting analysis of resistant strains compared to
that of original strains pretreatment. This represents a
limitation of the study. Two reasons might contribute to
the acquired drug resistant TB emergence under quali-
fied DOT and quality-assured drug apply under China’s
NTP. First, the selection of resistant mutants in mixed
bacterial population infected pretreatment due to killing
of susceptible strains by anti-TB drugs of SCC. Second,
infection of new drug resistant strains may be another
explanation for the acquired drug resistant TB emer-
gence during SCC [23].
Several researchers have reported that amplification of
resistance to additional anti-TB drugs while receiving
WHO recommended SCC [24]. Few data was reported
on the traits of acquired drug resistant TB emergence
receiving SCC with susceptible strains pretreatment.
However, it is important to identify drug-resistant cases
in time with standard treatment and prevent its dissem-
ination. We found the time point of acquired drug re-
sistant TB emergence was associated with drug
resistance patterns. Cases with MDR-TB development
were 8.3 times more likely to be late emergence com-
pared to the non-MDR-TB pattern. Moreover, the cases
with late emergence of acquired drug resistance are of
high risk to contribute to SCC failure. In line with other
studies, anti-TB drug resistance especially MDR-TB has
a negative impact on treatment outcome of SCC [8, 12,
16, 25–29]. Treatment success rate of MDR-TB cases
was 58 % in Peru and 60 % in Hongkong with SCC [8].
One study in rural counties of eastern China indicated
that the cure rate of MDR-TB and other drug resistant
TB were 58.3 % and 91.0 % of SCC [30]. Different from
these studies, we excluded the drug resistant TB cases
pretreatment to target on the characteristics of drug
resistant TB emergence during SCC and further explore
its impact on treatment outcome. Treatment success
rate of cases with acquired MDR-TB was 52.9 % while
82.2 % with non-MDR-TB, a little lower than that in
Peru, Hongkong and eastern China. We also analyzed
treatment success rate of 3 subgroups of non-MDR-TB
indicating that cases with any H resistance and E/S re-
sistance have higher treatment success rate around 90 %
while much lower treatment success rate of 61.5 % with
any R resistance with SCC. Some discordant impacts of
drug susceptibility patterns on treatment success are
reported in the literature [25, 31, 32]. This could be
explained by the different target population in our study.
The greatest finding of this study is that the time point
of acquired drug resistant TB emergence significantly
impacted treatment outcomes with SCC. Cases with
acquired drug resistant TB at 3–5 months were 25.7
times higher (OR, 25.7; 95 %CI, 4.3–153.4; P < 0.001)
than that of cases with acquired drug resistant TB within
2 months of SCC to experience treatment failure.
Table 3 Treatment outcomes of both pan-susceptible TB cases













1357(84.3) 44(84.6) 2(20.0) 46(74.1)
Failed 102(6.3) 6(11.5) 7(70.0) 13(21.0)
Died 36(2.2) 0(0.0) 1(10.0) 1(1.6)
Defaulted 39(2.4) 1(1.9) 0(0.0) 1(1.6)
Not evaluated 75(4.7) 1(1.9) 0(0.0) 1(1.6)
aPan-susceptible TB throughout in our study was defined as cases with TB
strains susceptible to all four first-line anti-TB drugs including isoniazid(H),
rifampicin (R), ethambutol (E), and streptomycin (S) both pretreatment and
throughout the therapy
Table 4 Effect of acquired drug resistant TB emergence during SCC on treatment failure
Time of acquired drug resistance emergence Total Treatment success n(%) Treatment failure n(%) Univariate analysis
OR(95 % CI) P value
≦2 months 52 44(84.6) 6(11.5) Reference <0.001*
3–5 months 10 2(20.0) 7(70.0) 25.7(4.3–153.4)
*P value was determined by Fisher’s Exact Test
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Besides drug resistant TB emergence time point, many
other factors including low BMI, smoking, and some be-
haviors such as alcohol consumption and drug abuse are
also associated with poor treatment outcomes [33–36].
Diabetes and baseline disease severity of TB also have
been shown to be independent risk factors for poor
treatment outcomes in previous studies [18, 26, 37–39].
As reported, the use of standard first-line anti- TB
treatment on cases with drug resistant TB pretreatment
have greater likelihood to get relapse, treatment failure
and acquired drug resistance [12, 40–42]. Therefore,
pretreatment DST were carried out for individual pa-
tients and those with any drug resistance were excluded
from our study and transferred to a DOTS-Plus program
with the consideration of providing a more tailored regi-
men for optimal treatment outcomes. Without doubt,
DST performed before and during SCC could provide
information to recognize drug resistant TB, particularly
MDR-TB. Our studies suggested DST should be taken
before treatment starting and subsequent DST should be
checked regarding patients who remain bacteriological
positive at the month 2 or 3 and it is better to provide
accordingly effective regimen rather than keeping using
SCC in the setting with drug resistant TB emergence
later after 2 months as these cases are more likely to fail
with SCC. The pressing need to prevent MDR-TB war-
rants this recommendation and this approach will help
decrease its transmission.
Our study has several limitations. First, we did not
provide longer follow-up information to evaluate recur-
rence rates and correlated risk factors for long-term
prognosis among successfully treated acquired drug-
resistant TB cases. Second, this study was limited by the
relatively small number of acquired drug resistant TB
cases during SCC. A larger sample could better present
the association of treatment failure and its impact fac-
tors. Hence, larger scale cohort studies are still needed
to further verify the findings of our study. Third, we
were not able to measure certain factors possibly related
to treatment failure, for example, comorbidities includ-
ing diabetes, chronic obstructive pulmonary disease,
chronic hepatitis, and bacterial load. Fourth, our study is
lack of DNA fingerprinting examination to differentiate
the origin of acquired drug resistant TB.
Despite these limitations, to date, this might be the first
study to evaluate the characteristics of acquired drug re-
sistant TB and its effect on treatment failure with SCC.
This study demonstrated later emergence of acquired drug
resistant TB during SCC is the prognostic risk factor for
treatment failure. Our findings may help relevant policy
makers to take more consideration of treatment manage-
ment on TB cases with potential failed outcomes. Early
detection of treatment failure will decrease transmission
and decrease likelihood of additional drug resistance
acquisition, providing more probability to choose ef-
fective regimen. Administration of effective regimen
may optimize cure rates and drug resistance acquisi-
tion may be avoided. Rapid, feasible and economical
culture and molecular biology methods such as Gen-
eXpert are imperative to be applied for identifying
drug resistant TB in time pretreatment or during SCC.
Effective and comprehensive TB control strategies with
adapted DOT is needed to prevent drug resistance
especially MDR-TB development. More strict infection
control and health education measures should be taken
to minimize the transmission of TB and drug resistant
TB bacilli in public and ensure patients adherence to
treatment preventing drug resistance development. In
addition, we expect more robust predictors developed
which could evaluate factors that could affect under-
lying pathological process of the disease being treated
and measure the effects of interventions on clinical
outcomes in multiple aspects [43].
Conclusion
Later emergence of acquired drug resistant TB during
SCC is prognostic risk factor for treatment failure. Early
detection of treatment failure will decrease transmission
and decrease likelihood of additional drug resistance ac-
quisition, providing more probability to choose effective
regimen.
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